Demo Data from SIGIR 2026 / reviewers in the wild / expert
Xueliang Li 0017
dblp:392/7547
· DBLP profile ↗
1ranked-venue papers
1as first author
1since 2021 · last 2024
0009-0008-7726-8298ORCID · verified
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1 · 1 first-author · 1 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 83% Medical and health informatics · 17% |
Topics — the 5 heaviest of 5, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery
drug combination prediction |
0.8 | 1 | 2024 | Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024 |
Bioinformatics and computational biology
drug discovery |
0.8 | 1 | 2024 | Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024 |
Bioinformatics and computational biology › drug discovery › drug combination prediction
drug synergy prediction |
0.8 | 1 | 2024 | Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024 |
Medical and health informatics › precision medicine
personalized treatment |
0.2 | 1 | 2024 | Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024 |
Medical and health informatics
precision medicine |
0.2 | 1 | 2024 | Dual-view jointly learning improves personalized drug synergy prediction · Bioinform. 2024 |
Methods — techniques the papers use, named apart from their topics
fine-tuning · 0.8dual-view jointly learning · 0.8
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2024 | Dual-view jointly learning improves personalized drug synergy predictionabstractMOTIVATION: Accurate and robust estimation of the synergistic drug combination is important for medicine precision. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. RESULTS: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and makes complementary contributes to the final prediction of the drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies. AVAILABILITY AND IMPLEMENTATION: Source code and data are available at https://github.com/LiHongCSBLab/JointSyn. Xueliang Li 0017, Bihan Shen, Fangyoumin Feng, Kunshi Li, Zhixuan Tang, Liangxiao Ma |
Bioinform. | 1 |